NYMOXIFY Trademark

Trademark Overview

On Friday, April 17, 2020, a trademark application was filed for NYMOXIFY with the United States Patent and Trademark Office. The USPTO has given the NYMOXIFY trademark a serial number of 88876244. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, November 13, 2023. This trademark is owned by Nymox Pharmaceutical Corporation. The NYMOXIFY trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for the treatment of benign prostatic hyperplasia and prostate cancer
nymoxify

General Information

Serial Number88876244
Word MarkNYMOXIFY
Filing DateFriday, April 17, 2020
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, November 13, 2023
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, August 18, 2020

Trademark Statements

Goods and ServicesPharmaceutical preparations for the treatment of benign prostatic hyperplasia and prostate cancer

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateSunday, April 26, 2020
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameNymox Pharmaceutical Corporation
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressNassau
BS
Party NameNymox Pharmaceutical Corporation
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressNassau
BS

Trademark Events

Event DateEvent Description
Monday, November 13, 2023ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Monday, November 13, 2023ABANDONMENT - NO USE STATEMENT FILED
Friday, March 17, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, March 16, 2023SOU EXTENSION 5 GRANTED
Monday, March 6, 2023SOU EXTENSION 5 FILED
Thursday, March 16, 2023CASE ASSIGNED TO INTENT TO USE PARALEGAL
Monday, March 6, 2023SOU TEAS EXTENSION RECEIVED
Wednesday, October 12, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, October 10, 2022SOU EXTENSION 4 GRANTED
Monday, October 10, 2022SOU EXTENSION 4 FILED
Monday, October 10, 2022SOU TEAS EXTENSION RECEIVED
Saturday, February 26, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, February 24, 2022SOU EXTENSION 3 GRANTED
Thursday, February 24, 2022SOU EXTENSION 3 FILED
Thursday, February 24, 2022SOU TEAS EXTENSION RECEIVED
Saturday, October 2, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, September 30, 2021SOU EXTENSION 2 GRANTED
Thursday, September 30, 2021SOU EXTENSION 2 FILED
Thursday, September 30, 2021SOU TEAS EXTENSION RECEIVED
Friday, February 19, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, February 17, 2021SOU EXTENSION 1 GRANTED
Wednesday, February 17, 2021SOU EXTENSION 1 FILED
Wednesday, February 17, 2021SOU TEAS EXTENSION RECEIVED
Tuesday, October 13, 2020NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, August 18, 2020OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, August 18, 2020PUBLISHED FOR OPPOSITION
Wednesday, July 29, 2020NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Friday, July 10, 2020APPROVED FOR PUB - PRINCIPAL REGISTER
Thursday, July 9, 2020ASSIGNED TO EXAMINER
Thursday, May 21, 2020PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED
Wednesday, May 20, 2020ASSIGNED TO LIE
Friday, May 15, 2020TEAS VOLUNTARY AMENDMENT RECEIVED
Sunday, April 26, 2020NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Tuesday, April 21, 2020NEW APPLICATION ENTERED

Related Keywords

nymoxify hyperplasia prostate cancer prostatic benign preparations treatment pharmaceutical